Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer

Ian Chau1 · Dung T. Le2 · Patrick A. Ott3 · Beata Korytowsky4 · Hannah Le4 · T. Kim Le4 · Ying Zhang4 · Teresa Sanchez4 · Gregory A. Maglinte4 · Melissa Laurie4 · Pranav Abraham4 · Dhiren Patel4 · Tong Shangguan4

Received: 10 June 2019 / Accepted: 5 September 2019 / Published online: 23 September 2019 © The Author(s) 2019, corrected publication 2019

Abstract
Background There are few third-line or later (3L+) treatment options for advanced/metastatic (adv/met) gastric cancer/gastroesophageal junction cancers (GC/GEJC). 3L+ Nivolumab demonstrated encouraging results in Asian patients in the ATTRACTION-2 study compared with placebo (12-month survival, 26% vs 11%), and in Western patients in the single-arm CheckMate 032 study (12-month survival, 44%). This analysis aimed to establish comparator cohorts of US patients receiving routine care in real-world (RW) clinical practice.

Methods A 2-step matching process generated RW cohorts from Flatiron Health’s oncology database (January 1, 2011–April 30, 2017), for comparison with each trial: (1) clinical trial eligibility criteria were applied; (2) patients were frequency-matched with trial arms for baseline variables significantly associated with survival. Median overall survival (OS) was calculated by Kaplan–Meier analysis from last treatment until death.

Results Of 742 adv/met GC/GEJC patients with at least 2 prior lines of therapy, matching generated 90 US RW ATTRACTION-2-matched patients (median OS: 3.5 months) versus 163 ATTRACTION-2 placebo patients (median OS: 4.1 months), and 100 US RW CheckMate 032-matched patients (median OS: 2.9 months) versus 42 CheckMate 032 nivolumab-treated patients (median OS: 8.5 months). Baseline characteristics were generally similar between clinical trial arms and RW-matched cohorts.

Conclusions We successfully developed RW cohorts for comparison with data from clinical trials, with comparable baseline characteristics. Survival in US patients receiving RW care was similar to that seen in Asian patients receiving placebo in ATTRACTION-2; survival with nivolumab in CheckMate 032 appeared favorable compared with US RW clinical practice.

Keywords Gastric cancer · Gastroesophageal junction cancer · Nivolumab

Introduction

The prevalence of gastric cancer (GC) is generally reported to be decreasing in recent decades [1], but remains the third leading cause of cancer-related mortality worldwide with approximately 783,000 deaths occurring annually [2]. In the United States (US), although prevalence and mortality of GC have fallen over the last 3 decades [1, 3], prognosis remains poor, with a 5-year survival of approximately 31% from 2008–2014 in the US [1]. The most recent report on US cancer statistics by the American Cancer Society, using incidence and mortality data from the National Center for Health Statistics, estimated that GC would account for approximately 27,510 new cases and 11,140 deaths in 2019 [4]. Clinically, management of gastroesophageal junction cancers (GEJC) of the proximal
Had a diagnosis of advanced or metastatic GC or GEJC January 1, 2011–April 30, 2017\(^a\) (\(n=2230\))

Were \(\geq 18\) years of age on index date (\(n=2230\))

Had \(\geq 2\) lines of systemic therapy after index date (\(n=742\))

**Matched to ATTRACTION-2**

ECOG PS 0 or 1 after index date (\(n=387\))

Had no other primary cancers \(\leq 5\) years after index date (except basal cell, squamous cell, or intramucosal carcinoma, carcinoma in situ, or bladder cancer) (\(n=357\))

Had none of the below conditions on or after index date:
- Autoimmune disease
- Brain metastases
- Interstitial lung disease or pulmonary fibrosis
- Diverticulitis or symptomatic gastrointestinal ulcerative disease
  (\(n=321\))

Were not pregnant on or after index date (\(n=321\))

Did not receive nivolumab, pembrolizumab, durvalumab, atezolizumab, or ipilimumab after index date (\(n=300\))

\(\geq 1\) month of recorded medical data\(^a\) in the database (\(n=300\))

**RW ATTRACTION-2 main cohort: \(n=300\)**

- Frequency matching criteria: distributions of initial diagnosis of disease stage (stage IV vs other), ECOG PS (0 vs 1), and primary tumor location (GC vs GEJC)

**RW ATTRACTION-2-matched cohort: \(n=90\)**

**Matched to CheckMate 032**

If HER2-positive, must have received trastuzumab (\(n=732\))

ECOG PS 0 or 1 after index date (\(n=383\))

Had no other primary cancers \(\leq 3\) years after index date (except basal cell, squamous cell, or intramucosal carcinoma, carcinoma in situ, or bladder cancer) (\(n=352\))

Had none of the below conditions on or after index date:
- Autoimmune disease
- Brain metastases
  (\(n=318\))

Were not pregnant on or after index date (\(n=318\))

Did not receive nivolumab, pembrolizumab, durvalumab, atezolizumab, or ipilimumab after index date (\(n=297\))

\(\geq 1\) month of recorded medical data\(^a\) in the database (\(n=297\))

**RW CheckMate 032 main cohort: \(n=297\)**

- Frequency matching criteria: distribution of ECOG PS (0 vs 1) and primary tumor location (GC vs GEJC)

**RW CheckMate 032-matched cohort: \(n=100\)**
Real-world comparators for GC/GEJC clinical trials

Fig. 1 Inclusion/exclusion criteria and patient attrition in RW cohorts matched to ATTRACT-2 placebo arm and CheckMate 032 nivolumab monotherapy arm. aExcluded patients who were enrolled in clinical trials. bDefined as data from outpatient physician office visits, nonfacility visits, laboratory visits, treatment/procedure visits, or medication administration. ECOG PS Eastern Cooperative Oncology Group performance status, GC gastric cancer, GEJC gastroesophageal junction cancer, HER2 human epidermal growth factor receptor-2, RW real-world

gastric cardia that infiltrate the distal esophagus generally follows guidance for GC [5].

Although GC/GEJC are less common in the US and other Western countries than in Asian countries [6], the burden attributable to this disease in the US remains substantial [7]. When patients with advanced/metastatic (adv/met) GC/GEJC reach the third-line setting, treatment options are limited and clinical outcomes remain poor [8–10]. Promising results have been reported in clinical trials using nivolumab in patients with adv/met GC/GEJC. The ATTRACT-2 phase III randomized clinical trial (NCT02267343) demonstrated that Asian patients who had received at least 2 prior regimens of systemic chemotherapy for GC/GEJC had improved overall survival (OS) with nivolumab compared with placebo (median OS: 5.3 months vs 4.1 months) [11]. However, it is unclear whether the survival benefit seen with nivolumab in Asian patients compared with placebo also applies to Western/US patients receiving routine clinical care for adv/met GC/GEJC. The CheckMate 032 phase I/II clinical trial (NCT01928394) reported encouraging survival with nivolumab monotherapy in Western patients who received at least 2 prior lines of systemic therapy (median OS: 8.5 months) [12]. However, this clinical trial did not include a control arm, and it is therefore unclear whether nivolumab confers a survival advantage in Western patients receiving routine clinical care.

In recent years, real-world (RW) analyses have increasingly been used to generate external comparator arms for clinical trials [13, 14]. Regulatory bodies have recognized the need for a broader, more flexible framework incorporating RW data for decision-making, as outlined in the 21st Century Cures Act [15, 16]. This study sought to leverage RW data by applying ATTRACT-2 and CheckMate 032 inclusion criteria and frequency-matching to develop RW comparator arms for these clinical trials, and assessed baseline characteristics, survival outcomes, and duration of therapy (DoT) in RW US patients receiving routine care for adv/met GC/GEJC.

Methods

Data source

This retrospective observational study used Flatiron Health’s longitudinal, demographically and geographically diverse database derived from electronic health record (EHR) data from January 1, 2011 through April 30, 2017. The Flatiron database includes data from over 265 cancer clinics (~ 800 sites of care) representing more than 2 million active US cancer patients receiving oncology care in a community practice setting [17], with demographics similar to those of the Surveillance, Epidemiology and End Results (SEER) program [1].

Flatiron data are categorized into disease-specific cohorts for subscription and analysis. The GC/GEJC cohort was used for this analysis. Flatiron patient-level EHR data include structured data (such as demographics, diagnosis codes [International Classification of Diseases, Ninth/Tenth Revisions], visits, laboratory tests, medications, and Eastern Cooperative Oncology Group [ECOG] performance status [PS]) in addition to unstructured data collected via technology-enabled chart abstraction from physicians’ notes and other unstructured documents. Institutional Review Board approval of the study protocol was obtained prior to study conduct and included a waiver of informed consent. Data provided to third parties were de-identified, and provisions were in place for preventing re-identification to protect patients’ confidentiality.

Study population

This study involved 2 analyses. One aimed to develop a RW cohort for comparison with patients in the ATTRACT-2 placebo arm; the second aimed to develop a RW cohort for comparison with patients in the CheckMate 032 nivolumab monotherapy arm (Fig. 1). After identifying a broad group of patients with adv/met GC/GEJC who had received at least 2 systemic treatments after index (the index date was defined as the date of first diagnosis of adv/met GC/GEJC), the RW cohorts for comparison with each trial were developed using a 2-step matching process: first, similar inclusion and exclusion criteria to the ATTRACT-2 placebo arm (“RW ATTRACT-2 main cohort”) and the CheckMate 032 nivolumab monotherapy arm (“RW CheckMate 032 main cohort”) were applied. Second, frequency-matching [18] was used to account for differences in population baseline variables that could influence OS, to further align the RW cohorts with the ATTRACT-2 placebo arm (“RW ATTRACT-2-matched cohort”) and the CheckMate 032 nivolumab monotherapy arm (“RW CheckMate 032-matched cohort”). Frequency matching is a process used to ensure that the distribution of important characteristics in a population cohort are aligned with those in a comparator cohort. For frequency matching, baseline characteristics in the RW main cohorts that were significantly associated with OS were identified by univariate analysis. Matched cohorts were then generated to ensure these characteristics were represented in the analysis. Eligible patients were subsequently
followed up until death, loss to follow-up, or end of study period (last observed visit date up to and including April 30, 2017), whichever occurred first. A subgroup analysis of the RW CheckMate 032 main cohort was conducted, assessing baseline characteristics and survival in patients diagnosed with GC compared with those diagnosed with GEJC.

**Study variables**

Baseline variables were recorded for patients in each RW cohort, including demographics (such as age, sex, race, and ethnicity), insurance/practice type, disease stage at initial diagnosis, length of follow-up, ECOG PS, primary tumor location (GC/GEJC), number of prior systemic therapies received, and types of prior systemic therapies. OS was defined as the time from last systemic treatment until death or censoring. Landmark survival rates at 6 and 12 months were defined as probability of survival at 6 and 12 months for each RW cohort. DoT for each line of therapy, defined as time from first to last administration date, was also reported; if DoT was recorded as less than a day, then DoT was considered 1 day. For reference, previously published outcomes data from ATTRACTION-2 and CheckMate 032 have also been included.

**Statistical analysis**

Descriptive statistics were used to describe baseline characteristics at index date; frequencies and proportions were used to describe categorical data, and means (standard deviations [SD]), and medians (ranges) were used for continuous data. Median OS was estimated by Kaplan–Meier. Univariate analyses were used to identify baseline variables in the RW cohorts that were significantly associated with OS. Frequency-matching was then used to align these baseline variables in the RW cohorts with those in the clinical trial arms.

**Results**

A total of 2230 patients with a diagnosis of adv/met GC/GEJC were identified in Flatiron between January 1, 2011 and April 30, 2017. Of these, 742 patients (33%) received at least 2 lines of systemic therapy after index (Fig. 1) and were eligible to enter the 2-step matching process for each clinical trial comparison.

**RW cohort matched to ATTRACTION-2 placebo arm**

After applying similar eligibility criteria to that used in the CheckMate 032 trial, a RW CheckMate 032 main cohort of 297 patients was identified; baseline characteristics for this cohort are presented in Online Resource 1. Univariate analyses showed that the primary tumor location (GC/GEJC), initial stage of disease (stage IV/other), and ECOG PS (0/1) were significantly associated with OS in this cohort (Online Resource 2). Frequency-matching on these significant factors resulted in a RW ATTRACTION-2-matched cohort of 90 patients for evaluation with the 163 patients in the ATTRACTION-2 placebo arm (Fig. 1). After frequency-matching, distributions of ECOG PS (ECOG PS 0: 30% vs 29%; ECOG PS 1: 70% vs 71%) and of stage IV disease at diagnosis (50% vs 50%) were similar between the RW ATTRACTION-2-matched cohort and the ATTRACTION-2 placebo arm, respectively (Table 1). The distribution of primary disease site differed between the RW ATTRACTION-2-matched cohort and ATTRACTION-2 placebo arm (GC: 77% vs 83%; GEJC: 23% vs 7%; unknown: 0% vs 10%); owing to underlying differences in US and Asian populations, this characteristic could not be fully matched.

Median OS (95% CI) from start of last systemic treatment in the RW ATTRACTION-2-matched cohort (3.5 [2.7–4.8] months) was broadly comparable with the ATTRACTION-2 placebo arm (4.1 [3.4–4.9] months); median OS (95% CI) in the ATTRACTION-2 nivolumab monotherapy arm was 5.3 (4.6–6.4) months (Fig. 2). Landmark survival rates at 6 and 12 months in the RW ATTRACTION-2-matched cohort were relatively similar to the ATTRACTION-2 placebo arm (6 months: 34% vs 35%, respectively; 12 months: 19% vs 11%, respectively); corresponding landmark survival rates in the ATTRACTION-2 nivolumab arm were 46% and 26% at 6 and 12 months, respectively (Fig. 2).

**RW cohort matched to CheckMate 032 nivolumab monotherapy arm**

After applying similar eligibility criteria to that used in the CheckMate 032 trial, a RW CheckMate 032 main cohort of 297 patients was identified; baseline characteristics for this cohort are presented in Online Resource 1. Univariate analyses showed that the primary tumor location (GC/GEJC) and ECOG PS (0/1) were significantly associated with OS in the RW CheckMate 032 main cohort (Online Resource 2). Frequency-matching on these factors resulted in a RW CheckMate 032-matched cohort of 100 patients for evaluation with the 42 patients in the CheckMate 032 nivolumab monotherapy arm (Table 1). After frequency-matching, distributions of ECOG PS (ECOG PS 0: 47% vs 48%; ECOG PS 1: 53% vs 52%) and of primary disease site (GC: 38% vs 38%; GEJC: 62% vs 62%) were similar between the RW CheckMate 032-matched cohort and the CheckMate 032 nivolumab monotherapy arm, respectively (Table 1). Median OS (95% CI) from start of last systemic treatment in the RW CheckMate
|                                | ATTRACTION-2 placebo arm (n=163) | RW ATTRACTION-2-matched cohort (n=90) | CheckMate 032 nivolumab arm (n=42) | RW CheckMate 032-matched cohort (n=100) |
|--------------------------------|----------------------------------|--------------------------------------|----------------------------------|--------------------------------------|
| **Age, y**                      |                                  |                                      |                                  |                                      |
| Mean (SD)                       | 60 (11.9)                        | 66 (12.6)                            | 57 (11.3)                        | 63 (11.8)                            |
| Median (range)                  | 61 (26–83)                       | 66 (33–85)                           | 58.5 (29–80)                     | 64 (33–85)                           |
| <65, n (%)                      | 95 (58)                          | 41 (46)                              | 32 (76)                          | 52 (52)                              |
| ≥65, n (%)                      | 68 (42)                          | 49 (54)                              | 10 (24)                          | 48 (48)                              |
| ≥75, n (%)                      | 14 (9)                           | 29 (32)                              | 2 (5)                            | 16 (16)                              |
| **Male, n (%)**                 |                                  |                                      |                                  |                                      |
| <65, n (%)                      | 95 (58)                          | 41 (46)                              | 32 (76)                          | 52 (52)                              |
| ≥65, n (%)                      | 68 (42)                          | 49 (54)                              | 10 (24)                          | 48 (48)                              |
| ≥75, n (%)                      | 14 (9)                           | 29 (32)                              | 2 (5)                            | 16 (16)                              |
| **Race, n (%)**                 |                                  |                                      |                                  |                                      |
| Asian                           | 163 (100)                        | 7 (8)                                | 0                                | 7 (7)                                |
| White                           | 0                                | 46 (51)                              | 39 (93)                          | 55 (55)                              |
| Black/African American          | 0                                | 9 (10)                               | 3 (7)                            | 6 (6)                                |
| Other                           | 0                                | 13 (14)                              | 0                                | 22 (22)                              |
| Unknown/missing                 | 0                                | 15 (17)                              | 0                                | 10 (10)                              |
| **Disease stage at diagnosis, n (%)** |                                  |                                      |                                  |                                      |
| Stage I and II                  | 21 (13)                          | 15 (17)                              | 2 (5)                            | 12 (12)                              |
| Stage III                       | 58 (36)                          | 24 (27)                              | 11 (26)                          | 17 (17)                              |
| Stage IV                        | 81 (50)                          | 45 (50)                              | 28 (67)                          | 67 (67)                              |
| Unknown                         | 3 (2)                            | 6 (7)                                | 1 (2)                            | 4 (4)                                |
| **ECOG PS, n (%)**              |                                  |                                      |                                  |                                      |
| 0                               | 47 (29)                          | 27 (30)                              | 20 (48)                          | 47 (47)                              |
| 1                               | 116 (71)                         | 63 (70)                              | 22 (52)                          | 53 (53)                              |
| **Primary site of disease, n (%)** |                                  |                                      |                                  |                                      |
| Gastric                         | 135 (83)                         | 69 (77)                              | 16 (38)                          | 38 (38)                              |
| Gastroesophageal junction        | 12 (7)                           | 21 (23)                              | 26 (62)                          | 62 (62)                              |
| Unknown                         | 16 (10)                          | 0                                   | 0                                | 0                                    |
| **No. of systemic treatment regimens received, n (%)** |                                  |                                      |                                  |                                      |
| 2                               | 29 (18)                          | 50 (56)                              | 18 (45)                          | 60 (60)                              |
| 3                               | 62 (38)                          | 28 (31)                              | 17 (40)                          | 27 (27)                              |
| 4+                              | 72 (44)                          | 12 (13)                              | 7 (17)                           | 13 (13)                              |
| **Regimens received after index, n (%)** |                                  |                                      |                                  |                                      |
| Pyrimidine analogues/fluoropyrimidine | 163 (100)                     | 85 (94)                              | 42 (100)                         | 94 (94)                              |
| Fluorouracil                    | 66 (40)                          | 65 (72)                              | 31 (74)                          | 72 (72)                              |
| Capecitabine                    | 68 (42)                          | 35 (39)                              | 20 (48)                          | 38 (38)                              |
| S-1 (gimeracil/oteracil potassium/tegafur) | 101 (62)                      | 0                                   | 1 (2)                            | 0                                    |
| Taxanes                         | 140 (86)                         | 66 (73)                              | 30 (71)                          | 74 (74)                              |
| Docetaxel                       | 52 (32)                          | 28 (31)                              | 21 (50)                          | 28 (28)                              |
| Paclitaxel                      | 100 (61)                         | 49 (54)                              | 14 (33)                          | 56 (56)                              |
| Paclitaxel albumin              | 11 (7)                           | 2 (2)                                | 0                                | 1 (1)                                |
| Platinum compounds              | 157 (96)                         | 83 (92)                              | 41 (98)                          | 93 (93)                              |
| Carboplatin                     | 2 (1)                            | 27 (30)                              | 12 (29)                          | 38 (38)                              |
| Cisplatin                       | 112 (69)                         | 24 (27)                              | 15 (36)                          | 30 (30)                              |
| Oxaliplatin                     | 82 (50)                          | 62 (69)                              | 33 (79)                          | 67 (67)                              |
| Irinotecan                      | 123 (75)                         | 24 (27)                              | 17 (40)                          | 25 (25)                              |
| Ramucirumab                     | 22 (13)                          | 38 (42)                              | 2 (5)                            | 37 (37)                              |
| Trastuzumab                     | 22 (13)                          | 9 (10)                               | 9 (21)                           | 15 (15)                              |
| Trastuzumab emtansine           | 2 (1)                            | 0                                   | 1 (2)                            | 0                                    |

*ECOG PS* Eastern Cooperative Oncology Group performance status, *GC* gastric cancer, *GEJC* gastroesophageal junction cancer, *RW* real-world, *SD* standard deviation

*a* At last systemic treatment in RW cohorts; at study entry in clinical trial arms

*b* Matched on initial diagnosis of disease stage (stage IV vs other), ECOG PS (0 vs 1), and primary site of disease

*c* Flatiron ECOG values obtained within 30 days after last systemic treatment

*d* Any time during observation period in RW cohorts; prior to start of 3L+ therapy in clinical trial arms
032-matched cohort was lower (2.9 [1.6–7.5] months) than in the CheckMate 032 nivolumab monotherapy arm (8.5 [3.3–15.0] months) (Fig. 3). Landmark survival in the RW CheckMate 032-matched cohort was 39% and 29% at 6 and 12 months, respectively; 12-month survival in the nivolumab monotherapy arm of CheckMate 032 was 44% (6-month survival was not reported).

When patients in the RW CheckMate 032 main cohort were stratified by tumor location (GC: \( n = 166 \); GEJC: \( n = 131 \)), the subgroup of patients with GC appeared less likely to be male (58% vs 85%) and younger than 65 years of age (40% vs 52%), and more likely to have an ECOG PS of 0 or 1 (75% vs 58%) than patients with GECJ (Online Resource 3). Median OS (95% CI) was 2.1 (1.8–3.0) months in patients with GC and 1.5 (1.2–2.0) months in patients with GEJC. Landmark survival appeared to be greater in patients with GC compared with patients with GEJC at 6 (30% vs 20%) and 12 months (16% vs 11%).

**Discussion**

This “matched” analysis provides US RW context for 2 clinical trials of nivolumab therapy of GC/GEJC. The 2-step matching process enabled generation of RW cohorts that were demonstrably more closely aligned (in terms of baseline characteristics) to patients in the respective clinical trial arms.

Patients receiving nivolumab in ATTRECTION-2 had significantly improved survival (5.3 months) compared with placebo [11]. Survival in patients receiving care in RW US clinical practice (3.5 months) appeared broadly comparable with patients receiving placebo in ATTRECTION-2 (4.1 months) after matching for inclusion criteria, although residual differences in primary disease site persisted after frequency-matching, possibly due to underlying differences between US RW patients and the Asian
patients in the placebo arm of ATTRACTION-2. In the matched CheckMate 032 analysis, OS of patients in the RW cohort was 6 months shorter than for patients receiving nivolumab monotherapy in the CheckMate 032 clinical trial [12]. Patients in the RW cohort and CheckMate 032 nivolumab arm appeared to be broadly aligned in terms of baseline demographics.

The CheckMate 032 clinical trial did not include a control arm; the U.S. Food and Drug Administration (FDA) has historically considered drug applications using single-arm trials of therapies only for indications in which no other therapy is available [19]. However, in recent years, the FDA has granted accelerated approval based on surrogate clinical outcomes data from single-arm studies [20–22], complemented by RW studies to generate evidence on safety and effectiveness [23, 24]. RW data can provide information on comparative effectiveness in circumstances in which obtaining equivalent data from randomized controlled trials may be time-consuming and costly [25]. Additionally, clinical trial data may not be representative of the wider population, and may underrepresent clinically important subpopulations. A recent retrospective review of patient records reported that a substantial proportion of patients who failed to meet hypothetical clinical trial eligibility criteria actually received therapy and had similar survival to patients who met the hypothetical eligibility criteria [26].

A previous US-based RW study (assessing data from both the IMS oncology database and Truven MarketScan) reported that approximately 20% of patients who received treatment for advanced GC subsequently received third-line therapy [27]. Given this substantial proportion of adv/met GC/GEJC patients who eventually receive third-line therapy, it is important that efficacious and safe treatments are identified. In this clinical setting, the ATTRACTION-2 and CheckMate 032 clinical trials demonstrate robust efficacy of nivolumab; the present RW analysis suggests that the survival seen with nivolumab in these 2 clinical trials is greater than in matched RW patients in US clinical practice.

The potential of programmed cell death ligand 1 inhibitors in this setting is further demonstrated by the results of the KEYNOTE-059 study [28].

To the authors’ knowledge, this is the first study to use clinical trial eligibility criteria and frequency-matching to generate RW cohorts of patients with GC/GEJC. This study is based on a relatively large sample size, and the Flatiron database is generally representative of the wider US
oncology community setting [29]. Flatiron demographics are generally similar to those of the SEER program [1]. The Flatiron Health database includes data obtained during treatment at participating clinics and health care providers only, and consequently lacks data related to treatments received at non-participating centers. Additionally, the possibility of selection bias (both in terms of participating centers and in patient entry) may exist, and caution should be taken when applying these findings to broader populations. As with any study assessing records obtained via EHRs, data were collected for disease management rather than for research purposes; consequently, misclassification and incomplete data entry are possible. Lastly, survival comparisons between real-world and clinical trial data must be interpreted with extreme caution; the proportion of patients lost to follow-up is likely to be higher in the real-world analysis, given the close scrutiny and monitoring applied to patients in clinical trials compared with those in real-world clinical practice.

This study used a 2-step matching process to generate 2 RW cohorts with similar baseline characteristics to the ATTRACTION-2 placebo and CheckMate 032 nivolumab monotherapy arms, respectively. These data suggest favorable outcomes with third or later line of nivolumab monotherapy of adv/met GC/GEJC compared with routine clinical care in US patients and with placebo in Asian patients. Notably, Western patients receiving non-immunotherapy as their last line of treatment had broadly similar outcomes to Asian patients receiving placebo, highlighting the relative ineffectiveness of treatments available in US RW practice for advanced lines of therapy. This analysis demonstrates that RW data can be used to generate suitable external control cohorts for clinical trial data lacking a control arm and provide insights on regional applicability of trial data.

**Acknowledgements**  All authors contributed to and approved the presentation; writing assistance was provided by Martin Bell, PhD, of Evidence Scientific Solutions, funded by Bristol-Myers Squibb.

**Compliance with ethical standards**

**Conflict of interest**  Ian Chau has participated in advisory boards for AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, Five Prime Therapeutics, Merck Serono, MSD, Oncologie International, Pierre Fabre, and Roche, and received honorarium and/or research funding from Eli Lilly, Janssen-Cilag, Merck Serono, and Sanoﬁ. Dung T. Le has received research funding from, and participated in advisory boards for, Bristol-Myers Squibb and Merck Serono, and has received speaker’s honoraria from Merck Serono. Patrick A. Ott has received research funding and/or consultancy fees from Amgen, ARMO Biosciences, Array, AstraZeneca, Bristol-Myers Squibb, Celldex, CytoImmX, Genentech, Merck Serono, Neon Therapeutics, Novartis, and Pfizer. Beata Korytowsky, T. Kim Le, Ying Zhang, Teresa Sanchez, Melissa Laurie, Pranav Abraham, Dhiren Patel, and Tong Shangguan are employees of, and hold stock in, Bristol-Myers Squibb. Hannah Le and Gregory A. Maglinte were employed by Bristol-Myers Squibb at the time of analysis.

**Informed consent**  Institutional Review Board approval of the study protocol was obtained prior to study conduct and included a waiver of informed consent.

**Open Access**  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, et al. SEER Cancer Statistics Review, 1975–2014. 2017. https://seer.cancer.gov/csr/1975_2014/. Accessed 24 June 2018

2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

3. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290–314.

4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Gastric cancer. 2018. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed on 24 Jun 2018.

6. Bang YJ, Yalcin S, Roth A, Hitier S, Ter-Ovanesov M, Wu CW, et al. Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics. Asia Pac J Clin Oncol. 2014;10(1):38–52.

7. Karve S, Lorenzo M, Liepa AM, Hess LM, Kaye JA, Calingaert B. Treatment patterns, costs, and survival among Medicare-enrolled elderly patients diagnosed with advanced stage gastric cancer: analysis of a linked population-based cancer registry and administrative claims database. J Gastric Cancer. 2015;15(2):87–104.

8. Erdem GU, Bozkaya Y, Ozdemir NY, Demirici NS, Yazici O, Zengin N. 5 fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidines, platinum, anthracycline, and taxane. BOSN J Basic Med Sci. 2018;18(2):170–7.

9. Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al. Randomized, Double-blind, placebo-controlled phase III trial of apanitib in patients with chemotherapy-refractory advanced or metastatic gastric cancer. Bosn J Basic Med Sci. 2018;18(2):170–7.

10. Nishimura T, Iwasa S, Nagashima K, Okita N, Takashima A, Honma Y, et al. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. Gastric Cancer. 2017;20(4):655–62.

11. Kang YK, Boku N, Sato H, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538–12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–71.

12. Ott P, Calvo E, Sharma P, Jaeger D, Ascietto P, Chau I, et al. O-007Nivolumab monotherapy in patients with advanced gastric
or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: sub-analysis of the CheckMate 032 study. Ann Oncol. 2017;28(3):262006.

13. Davies J, Martinez M, Delmar P, Coudert M, Bordogna W, Golding S, et al. Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib. J Comp Eff Res. 2018;7(9):855–65.

14. Fralick M, Kesselheim AS, Avorn J, Schneeweiss S. Use of health care databases to support supplemental indications of approved medications. JAMA Intern Med. 2018;178(1):55–63.

15. Kesselheim AS, Avorn J. New, “21st Century Cures” legislation: speed and ease vs science. JAMA. 2017;317(6):581–2.

16. US Food & Drug Administration. Framework for FDA’s real-world evidence program. 2018. https://www.fda.gov/media/120060/download. Accessed on 03 May 2019.

17. Flatiron Health. Flatiron Health Electronic Health Record database. 2017. https://www.flatiron.com/life-sciences. Accessed on 19 Oct 2017.

18. Gail MH. Frequency matching. Encyclopedia of Biostatistics. New York: Wiley; 2005.

19. US Food & Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics. 2007. https://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf. Accessed on 25 June 2018.

20. Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R. Accelerated approval of oncology products: the Food and Drug Administration experience. J Natl Cancer Inst. 2011;103(8):636–44.

21. Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med. 2015;175(12):1992–4.

22. Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374–85.

23. US Food & Drug Administration. Primer on drug development. 2018. https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/OCE/UCM590164.pdf. Accessed on 25 June 2018.

24. Cowey CL, Mahnke L, Espirito J, Helwig C, Oksen D, Bharmal M. Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. Future Oncol. 2017;13(19):1699–710.

25. Bothwell LE, Greene JA, Podolsky SH, Jones DS. Assessing the gold standard-lessons from the history of RCTs. N Engl J Med. 2016;374(22):2175–81.

26. Al-Baimani K, Jonker H, Zhang T, Goss GD, Laurie SA, Nicholas G, et al. Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients? Curr Oncol. 2018;25(4):e291–e297.

27. Hess LM, Michael D, Mytelka DS, Beyrer J, Liepa AM, Nicol S. Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data. Gastric Cancer. 2016;19(2):607–15.

28. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4(5):e180013.

29. Berger ML, Curtis MD, Smith G, Harnett J, Abernethy AP. Opportunities and challenges in leveraging electronic health record data in oncology. Future Oncol. 2016;12(10):1261–74.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.